Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.69 | N/A | +2.68% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.69 | N/A | +2.68% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management highlighted the positive EPS surprise as a sign of operational efficiency. However, they did not provide specific revenue guidance.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized their commitment to ongoing research and development.
Bristol Myers Squibb's earnings report showed a positive EPS surprise, indicating better-than-expected profitability. However, the stock fell by 2.37%, likely due to the absence of revenue figures and guidance, which left investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Jul 25, 2016